CredoScientia - Bibliothèque

Revisiting the role of local treatments in the era of targeted therapy and immunotherapy for hepatocellular carcinoma.

The advent of targeted therapy and immunotherapy has revolutionised the management of hepatocellular carcinoma (HCC) patients with all stages, dramatically improving their survival outcomes. Currently…

Thérapies de Conversion

Du, J. J., Yang, F., Dong, W., Zhang, Z. Y., Cheng, Q., & Zhang, E. L. (2025). Revisiting the role of local treatments in the era of targeted therapy and immunotherapy for hepatocellular carcinoma.. World J Surg Oncol, 23(1), 323. https://doi.org/10.1186/s12957-025-03963-3

27/08/2025 Lire →

Efficacy and safety of reduced thromboprophylaxis with low molecular weight heparin for hepatocellular carcinoma after conversion therapy.

BACKGROUND: Tyrosine kinase inhibitors (TKIs) impairs factor Xa (FXa)-mediated coagulation. This study aims to assess the safety and feasibility of reduced thromboprophylaxis with low molecular weight…

Thérapies de Conversion

Zhang, X., & Ai, Z. (2025). Efficacy and safety of reduced thromboprophylaxis with low molecular weight heparin for hepatocellular carcinoma after conversion therapy.. BMC Gastroenterol, 25(1), 606. https://doi.org/10.1186/s12876-025-04208-z

20/08/2025 Lire →

Prognostic Value of Clinical Complete Response for Patients with Initially Unresectable Hepatocellular Carcinoma after Conversion with Triple Therapy.

INTRODUCTION: Accurately predicting the outcomes of conversion therapy among patients with initially unresectable hepatocellular carcinoma (uHCC) remains a challenge. Clinical complete response (cCR) …

Thérapies de Conversion

Wu, J. Y., Zeng, Z. X., Li, Y. N., Zhang, Z. B., Zhuang, S. W., Li, B., Zhou, J. Y., Li, S. Q., Liu, D. Y., Li, H., Ou, X. Y., Wu, J. Y., & Yan, M. L. (2025). Prognostic Value of Clinical Complete Response for Patients with Initially Unresectable Hepatocellular Carcinoma after Conversion with Triple Therapy.. Liver Cancer, 14(4), 420-434. https://doi.org/10.1159/000543602

01/08/2025 Lire →

Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in inte

Thérapies de Conversion

Yang, D. L., Ye, L., Zeng, F. J., Liu, J., Yao, H. B., Nong, J. L., Liu, S. P., Peng, N., Li, W. F., Wu, P. S., Qin, C., Su, Z., Ou, J. J., Dong, X. F., Yan, Y. H., Zhong, T. M., Mao, X. S., Wu, M. S., Chen, Y. Z., … GUIDANCE, i. n. v. e. s. t. i. g. a. t. o. r. s. (2025). Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in inte. Hepatology, 82(2), E40. https://doi.org/10.1097/HEP.0000000000001401

01/08/2025 Lire →

Laparoscopic Extended Segmentectomy 8 with Right Hepatic Vein Resection After Conversion Therapy for Advanced Intrahepatic Cholangiocarcinoma.

BACKGROUND: Most patients with intrahepatic cholangiocarcinoma (ICC) are diagnosed at advanced stages and are thus ineligible for surgery. Recently, a combination of immunotherapy, chemotherapy, and l…

Thérapies de Conversion

Tan, W., Wei, J., Chen, Y., & Shang, C. (2025). Laparoscopic Extended Segmentectomy 8 with Right Hepatic Vein Resection After Conversion Therapy for Advanced Intrahepatic Cholangiocarcinoma.. Ann Surg Oncol, 32(8), 5711-5712. https://doi.org/10.1245/s10434-025-17392-9

01/08/2025 Lire →

The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan.

BACKGROUND: This study aimed to investigate the changes in oncological resection status in patients with unresectable hepatocellular carcinoma (u-HCC) receiving atezolizumab plus bevacizumab (Atez/Bev…

Thérapies de Conversion

Shimose, S., Saeki, I., Ito, T., Takeuchi, Y., Tani, J., Tomonari, T., Sasaki, R., Sasaki, K., Kakizaki, S., Hatanaka, T., Iwamoto, H., Tanabe, N., Yamamoto, T., Naganuma, A., Shirono, T., Kanayama, Y., Nishina, S., Takayama, T., Kobara, H., … representing, t. h. e. . H. e. p. a. t. o. l. o. g. y. . I. n. V. e. s. t. i. g. a. t. o. r. . E. x. p. e. r. t. s. . i. n. . J. a. p. a. n. . (. H. I. V. E. -. J. ). . S. t. u. d. y. . G. r. o. u. p. (2025). The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan.. Hepatol Int, 19(4), 846-855. https://doi.org/10.1007/s12072-025-10781-y

01/08/2025 Lire →

Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate

BACKGROUND AND AIMS: Various conversion therapy options have become available to patients with unresectable HCC, but which conversion therapy is optimal for which type of patient is controversial. Thi…

Thérapies de Conversion

Yang, D. L., Ye, L., Zeng, F. J., Liu, J., Yao, H. B., Nong, J. L., Liu, S. P., Peng, N., Li, W. F., Wu, P. S., Qin, C., Su, Z., Ou, J. J., Dong, X. F., Yan, Y. H., Zhong, T. M., Mao, X. S., Wu, M. S., Chen, Y. Z., … GUIDANCE, i. n. v. e. s. t. i. g. a. t. o. r. s. (2025). Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate . Hepatology, 82(2), 357-369. https://doi.org/10.1097/HEP.0000000000001229

01/08/2025 Lire →

Current status and advances in the treatment of colorectal cancer with liver metastases.

The incidence of colorectal cancer is gradually increasing, and a majority of patients are diagnosed with distant metastases at the time of initial diagnosis, with the liver being the most common site…

Thérapies de Conversion

Liu, W. X., Jiang, C., & Li, J. X. (2025). Current status and advances in the treatment of colorectal cancer with liver metastases.. World J Clin Oncol, 16(7), 107438. https://doi.org/10.5306/wjco.v16.i7.107438

24/07/2025 Lire →

[Advances in Surgical Treatment Following Conversion Therapy for Pancreatic Cancer].

Pancreatic cancer is characterized by an insidious onset, high invasiveness, and poor response to treatment. Radical resection remains the only potentially curative approach currently available. Howev…

Thérapies de Conversion

Meng, L., Li, Y., & Peng, B. (2025). [Advances in Surgical Treatment Following Conversion Therapy for Pancreatic Cancer].. Sichuan Da Xue Xue Bao Yi Xue Ban, 56(4), 1003-1010. https://doi.org/10.12182/20250760201

20/07/2025 Lire →

Conversion therapy and R0 resection for pancreatic cancer with multiple liver metastases: a case report.

BACKGROUND: Pancreatic cancer has a high degree of malignancy, poor prognosis, and short survival time. Surgical resection is the main treatment for pancreatic cancer, but the resection rate is only 2…

Thérapies de Conversion

Dong, S., Gao, Y., Wang, Z., Liang, J., & Jiang, A. (2025). Conversion therapy and R0 resection for pancreatic cancer with multiple liver metastases: a case report.. J Cancer Res Clin Oncol, 151(7), 200. https://doi.org/10.1007/s00432-025-06180-3

03/07/2025 Lire →

[Advancements and prospects of minimally invasive surgery for gastric cancer].

With the advancement of diagnostic/therapeutic technologies and evolving treatment paradigms, the management of gastric cancer has progressively transitioned toward precision medicine and minimally in…

Thérapies de Conversion

Chen, L., & Li, L. (2025). [Advancements and prospects of minimally invasive surgery for gastric cancer].. Zhonghua Wai Ke Za Zhi, 63(7), 546-551. https://doi.org/10.3760/cma.j.cn112139-20250128-00046

01/07/2025 Lire →

Liver transplantation in a patient with metastatic hepatocellular carcinoma after downstaging with single-agent immunotherapy: the first case report.

BACKGROUND: Immunotherapy in hepatocellular carcinoma (HCC) has changed the clinical practice for unresectable and advanced setting after the approvals of atezolizumab plus bevacizumab and durvalumab …

Thérapies de Conversion

Pirozzi, A., Hoyek, C., Abidoye, O., Okano, N., Nguyen, M. C., Byrne, T., Aqel, B., Chascsa, D., Alzubaidi, S., Rimassa, L., Bekaii-Saab, T., & Borad, M. J. (2025). Liver transplantation in a patient with metastatic hepatocellular carcinoma after downstaging with single-agent immunotherapy: the first case report.. J Gastrointest Oncol, 16(3), 1321-1330. https://doi.org/10.21037/jgo-24-764

30/06/2025 Lire →